Hims & Hers Health (HIMS) Stock Price, Chart, Company Profile & AI Analysis
Hims & Hers, launched in 2017, is a telehealth platform that connects patients and healthcare providers to offer treatment options for specialties like erectile dysfunction, hair loss, skin care, mental health, and weight loss... Show more
Hims & Hers Health (HIMS) Stock Analysis: GLP-1 Pivot Reshapes Growth Path
Key Takeaways
- Hims & Hers Health stock has shown volatility in recent weeks amid regulatory shifts in weight-loss drugs and anticipation for Q1 2026 earnings.
- Partnerships with Novo Nordisk for branded GLP-1s (glucagon-like peptide-1 agonists, medications for weight management) bolster platform expansion.
- Analysts maintain a consensus Hold to Overweight rating with price targets averaging around $27–$30.
- Full-year 2026 revenue guidance of $2.7–$2.9 billion signals continued subscriber growth beyond core telehealth offerings.
- Recent board addition and peptide-related FDA discussions highlight strategic and regulatory evolution.
Current Market Snapshot
Hims & Hers Health (HIMS) has navigated choppy waters in recent trading sessions, reflecting broader pressures in the telehealth and weight-loss sectors. The stock, with a market cap exceeding $6 billion, a trailing P/E ratio (price-to-earnings ratio, a valuation metric comparing stock price to earnings) of 55 and beta of 2.42 indicating heightened volatility, has experienced sharp swings tied to news on compounded medications and branded drug partnerships. Recent weeks saw pullbacks amid valuation concerns, offset by optimism around platform diversification and upcoming earnings. Investors remain focused on execution in personalized health solutions amid competitive and regulatory dynamics.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases a curated selection of the top 25 performers from its library of over 350 AI trading bots, designed to adapt to current market conditions across thousands of tickers. These bots employ advanced machine learning models with varying strategies, timeframes from 5 to 60 minutes, and focus areas like semiconductors, industrials, ETFs, and volatility plays. Standout stats include annualized returns ranging from 23% to over 285%, win rates of 50–88%, and trade counts from 7 to dozens per bot, often managing multi-ticker portfolios with take-profit/stop-loss corridors. For instance, space infrastructure bots have posted 285% annualized gains with 72% win rates on short timeframes. While no trending bots specifically target HIMS, their diverse styles—trend-following, fundamental analysis, and high-frequency—offer tools for volatile stocks like those in telehealth. Explore these dynamic options tailored to today's markets at the Trending AI Robots page to enhance your trading edge.
Recent Developments Driving HIMS Price Action
Hims & Hers Health, a leading telehealth platform offering personalized treatments for wellness categories including weight loss, sexual health, and dermatology, has seen its stock price fluctuate amid key updates in the past 30 days. The company, which reported Q4 2025 revenue of $617.8 million (up 28% year-over-year) and raised full-year 2026 guidance to $2.7–$2.9 billion, continues to expand its subscriber base to over 2.5 million.
A pivotal development was the March 26 expansion of its partnership with Novo Nordisk, making FDA-approved GLP-1 drugs like Wegovy and Ozempic available via the Hims platform. This followed earlier resolutions of legal disputes, shifting from compounded versions to branded offerings and alleviating prior overhangs from lawsuits and FDA scrutiny on compounding pharmacies. The move drove positive sentiment, contributing to multi-day rallies as it validates Hims' direct-to-consumer model for blockbuster weight-loss treatments.
On April 16, shares surged over 7–11% after the FDA signaled review of broader peptides access for compounding, seen as a long-term win for telehealth providers like Hims despite ongoing restrictions on GLP-1 active ingredients. Analysts noted this could reopen doors for peptide-based therapies in areas like wound healing and insomnia.
April 13 marked the announcement of Q1 2026 earnings on May 11, heightening anticipation with consensus expecting $616–$620 million revenue and $0.03–$0.04 EPS. Pre-earnings positioning led to volatility, with shares dipping on valuation checks post-pullbacks but rebounding on growth narratives around Hims Labs AI and GLP-1 integration.
Analyst actions influenced sentiment: JP Morgan initiated Overweight with $35 target on April 24, citing catalysts; BofA raised to $32 (Neutral). Consensus holds at Hold/Overweight, average target $27–$30, reflecting balanced views on execution risks versus expansion.
On April 28, the nomination of Kofi Amoo-Gottfried to the board signaled governance strengthening. Broader pressures from competitors like Amazon's weight management push and data breach disclosures added short-term drags, but platform DTC expansions supported resilience. Overall, these events linked to 10–11% single-day gains and subsequent consolidations, underscoring HIMS' sensitivity to regulatory and partnership news.
2026 Outlook and Key Factors to Monitor
As Hims & Hers Health advances through 2026, investors should track execution on its $2.7–$2.9 billion revenue guidance, driven by subscriber growth to personalized health verticals and international expansion via potential acquisitions like prior Eucalyptus interest. The shift to branded GLP-1 partnerships with Novo Nordisk and possible Eli Lilly ties reduces compounding risks but introduces margin pressures from higher drug costs; monitor Adjusted EBITDA margins targeting 11–13%.
Regulatory landscape remains critical, with FDA peptide reviews and compounding eligibility potentially unlocking new therapies, balanced against litigation from pharma giants. Competitive positioning against Amazon One Medical and GoodRx in DTC weight loss will test platform stickiness. Opportunities lie in AI-enhanced Hims Labs for diagnostics, diversified offerings in mental health and cardio, and subscriber monetization via higher revenue per user. Risks include execution on back-half weighted growth, cost inflation, and macroeconomic sensitivity in discretionary wellness spending. Consensus EPS growth to $0.67 underscores long-term potential if trends hold.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
Momentum Indicator for HIMS turns positive, indicating new upward trend
HIMS saw its Momentum Indicator move above the 0 level on May 27, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 83 similar instances where the indicator turned positive. In of the 83 cases, the stock moved higher in the following days. The odds of a move higher are at .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for HIMS just turned positive on May 29, 2026. Looking at past instances where HIMS's MACD turned positive, the stock continued to rise in of 47 cases over the following month. The odds of a continued upward trend are .
HIMS moved above its 50-day moving average on May 27, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for HIMS crossed bullishly above the 50-day moving average on June 01, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .
Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where HIMS advanced for three days, in of 271 cases, the price rose further within the following month. The odds of a continued upward trend are .
Bearish Trend Analysis
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where HIMS declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
HIMS broke above its upper Bollinger Band on June 01, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for HIMS entered a downward trend on May 29, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. HIMS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. HIMS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock better than average.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (14.970) is normal, around the industry mean (146.073). P/E Ratio (57.137) is within average values for comparable stocks, (97.164). Projected Growth (PEG Ratio) (2.155) is also within normal values, averaging (1.600). HIMS has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.032). P/S Ratio (3.090) is also within normal values, averaging (96.656).
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a company, which is involved in real estate investment trusts
Industry PharmaceuticalsGeneric